Walter Heldwein

TL;DR: It is concluded that ursodeoxycholic acid is beneficial in reducing disease activity in patients with primary sclerosing cholangitis and histopathological features improved significantly, as evaluated by multiparametric score.

TL;DR: Data do not confirm the supposed increased risk for IFN‐α–induced mental side effects and dropouts in psychiatric patients if interdisciplinary care and antidepressant treatment are available, and preexisting psychiatric disorders or present methadone substitution should no longer be regarded as contraindications to treatment of chronic hepatitis C with IFN-α and ribavirin in an interdisciplinary setting.

TL;DR: Colonoscopic polypectomy is associated with a 10% rate of complications, but three-quarters of these are of minor clinical significance, and guidelines for intensified follow-up afterpolypectomy should be based on the size, location, and number of a patient's polyps.

TL;DR: The combination of 120 mg omeprazole daily and 2.25 g amoxicillin daily with its H. pylori cure rate of around 90% is one of the best tolerated and most effective treatment regimens.

TL;DR: Despite a moderate reduction in inflammatory lipid mediators by dietary n‐3 fatty acids and limited morphological improvement in chronic inflammatory bowel disease, the clinical benefit seems to be confined to patients with ulcerative colitis.